When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.

That's why we have released our Free Precious Metals Investment Guide.

Matthew M. Walsh net worth and biography

Matthew Walsh Biography and Net Worth

Director of Certara

Mr. Matthew Walsh currently serves as Executive Vice President and Chief Financial Officer of Organon & Co., a global pharmaceutical business within Merck that was spun off in 2021. Prior to Organon, he served as Executive Vice President and Chief Financial Officer of Allergan, a publicly traded, global biopharmaceutical company, from 2018 until the sale of the company to Abbvie in 2020. From 2008 to 2018, Mr. Walsh served as Chief Financial Officer of Catalent, a global provider of delivery technologies, development, and manufacturing solutions to the life sciences industry. During his tenure, Catalent successfully completed the largest healthcare IPO of 2014. Before Catalent, from 2006 to 2008, he was President, Chief Financial Officer and Acting Chief Executive Officer at Escala Group, Inc.

Mr. Walsh previously held a variety of finance leadership roles at industrial manufacturer GenTek, Inc., including Chief Financial Officer, Treasurer, and Group Controller. He served on the board of directors of Multicolor Corporation from 2015 to 2017.

Mr. Walsh earned his Bachelor of Science degree in chemical engineering from Cornell University, and an M.B.A. from Cornell University, SC Johnson School of Management. Mr. Walsh is a CFA® charterholder.

What is Matthew M. Walsh's net worth?: The estimated net worth of Matthew M. Walsh is at least $2.78 million as of November 14th, 2022. Mr. Walsh owns 167,901 shares of Certara stock worth more than $2,782,120 as of April 27th. This net worth estimate does not reflect any other assets that Mr. Walsh may own. Learn More about Matthew M. Walsh's net worth.
How do I contact Matthew M. Walsh?: The corporate mailing address for Mr. Walsh and other Certara executives is 100 OVERLOOK CENTER SUITE 101, PRINCETON NJ, 08540. Certara can also be reached via phone at 609-716-7900 and via email at [email protected]. Learn More on Matthew M. Walsh's contact information.
Has Matthew M. Walsh been buying or selling shares of Certara?: Matthew M. Walsh has not been actively trading shares of Certara during the last ninety days. Most recently, Matthew M. Walsh sold 12,059 shares of the business's stock in a transaction on Monday, November 14th. The shares were sold at an average price of $14.74, for a transaction totalling $177,749.66. Following the completion of the sale, the director now directly owns 167,901 shares of the company's stock, valued at $2,474,860.74. Learn More on Matthew M. Walsh's trading history.
Who are Certara's active insiders?: Certara's insider roster includes Robert Aspbury (Insider), Eran Broshy (Director), James Cashman, III (Director), Jieun Choe (Insider), Justin Edge (Insider), William Feehery (CEO), Stephen McLean (Director), Leif Pedersen (Insider), Craig Rayner (Insider), Michael Schemick (CFO), Mason Slaine (Director), Patrick Smith (Insider), Richard Traynor (SVP), and Matthew Walsh (Director). Learn More on Certara's active insiders.
Are insiders buying or selling shares of Certara?: During the last year, Certara insiders bought shares 1 times. They purchased a total of 193 shares worth more than $3,107.30. During the last year, insiders at the sold shares 7 times. They sold a total of 104,755 shares worth more than $1,776,756.55. The most recent insider tranaction occured on April, 2nd when insider Patrick F Smith sold 14,427 shares worth more than $243,094.95. Insiders at Certara own 2.6% of the company. Learn More about insider trades at Certara.
Information on this page was last updated on 4/2/2024.

Matthew M. Walsh Insider Trading History at Certara

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/14/2022	Sell	12,059	$14.74	$177,749.66	167,901

Matthew M. Walsh Buying and Selling Activity at Certara

Certara Company Overview

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $16.57

$16.21

$16.78

50 Day Range

MA: $17.69

$15.93

$19.45

2 Week Range

Now: $16.57

$11.81

$24.64

Volume

321,643 shs

Average Volume

533,272 shs

Market Capitalization

$2.65 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63

The Gold Grab of the Century

From Colonial Metals | Ad